Incidence and Predictors of Severe Adverse Drug Reaction Among Patients on Antiretroviral Therapy in Tigray, Ethiopia: A Retrospective Cohort Study

References

• UNAIDS. UNAIDS_Terminology_Guidelines_MidtermAdditions_20111009. October, 2011.
   Google Scholar
• HIV/ AIDS, J.U.N.P.o. Global HIV & AIDS Statistics—2018 Fact Sheet. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Nygren-Krug H. The Joint United Nations Programme on HIV/AIDS. Human Rights in Global Health: Rights-Based Governance for a Globalizing World; 2018:281.
   Google Scholar
• Office, F.H.A.P.a.C. HIV Prevention in Ethiopia National Road Map 2018–2020. November, 2018.
   Google Scholar
• Organization(WHO), W.H. Clinical Aspects of ADRs in HIV and ARV Toxicity Monitoring Approaches. Gaborone, Botswana. June 26, 2018.
   Google Scholar
• Shet A, Antony J, Arumugam K, et al. Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PLoS One. 2014;9(3):e91028. doi:10.1371/journal.pone.0091028
   PubMed Web of Science ®Google Scholar
• Eluwa GI, Badru T, Akpoigbe KJ. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12(1):1–9. doi:10.1186/1472-6904-12-1
   Google Scholar
• Gudina EK, Teklu AM, Berhan A, et al. Magnitude of antiretroviral drug toxicity in adult HIV patients in Ethiopia: a cohort study at seven teaching hospitals. Ethiop J Health Sci. 2017;27(1):39–52. doi:10.4314/ejhs.v27i1.5S
   Google Scholar
• Lartey M, Asante-Quashie A, Essel A, Kenu E, Ganu V. Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana. Pan Afr Med J; 2014:18.
   Google Scholar
• Chaisson RE, Schecter GF, Theuer CP, et al. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis. 1987;136(3):570–574. doi:10.1164/ajrccm/136.3.570
   PubMed Web of Science ®Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83–94. doi:10.1016/j.jsps.2013.02.003
   PubMed Web of Science ®Google Scholar
• Organization, W.H. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization; 2016.
   Google Scholar
• Kibret GD, Ayele TA, Tesfahun A. Incidence and Predictors of Sever Adverse Drug Reactions Among Patients on Antiretroviral Therapy at Debre Markos Referral Hospital, Northwest Ethiopia. Research square; 2019.
   Google Scholar
• Obiako OR, Muktar HM, Garko SB, et al. Adverse reactions associated with antiretroviral regimens in adult patients of a university teaching hospital HIV program in Zaria, Northern Nigeria: an observational cohort study. J Antivir Antiretrovir. 2012;4:6–13.
   Google Scholar
• Kindie E, Alamrew Anteneh Z, Worku E, Maga G. Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City, Northwest Ethiopia. PLoS One. 2017;12(12):e0189322. doi:10.1371/journal.pone.0189322
   Web of Science ®Google Scholar
• Rajesh R, Sonika S, Sudha V, et al. Association between medication adherence outcomes and adverse drug reactions to highly active antiretroviral therapy in Indian human immunodeficiency virus-positive patients. J Young Pharm. 2012;4(4):250–260. doi:10.4103/0975-1483.104369
   PubMedGoogle Scholar
• Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. 2016;16(5):481. doi:10.7861/clinmedicine.16-5-481
   PubMed Web of Science ®Google Scholar
• Wolfe D, Yazdi F, Kanji S, et al. Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: a systematic review of systematic reviews. PLoS One. 2018;13(10):e0205426. doi:10.1371/journal.pone.0205426
   Web of Science ®Google Scholar
• Sood A, Prajapati H, Bhagra S, et al. Characterization and comparative analysis of ADRs of various ART regimens: experience of our medical college from Western Himalayan region. Int J Res Med Sci. 2017;5(2):659–665. doi:10.18203/2320-6012.ijrms20170170
   Google Scholar
• Anlay DZ, Alemayehu ZA, Dachew BA. Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study. AIDS Res Ther. 2016;13(1):1–8. doi:10.1186/s12981-016-0095-x
   PubMed Web of Science ®Google Scholar
• Birlie B, Braekers R, Awoke T, et al. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia. BMC Infect Dis. 2017;17(1):1–13. doi:10.1186/s12879-017-2533-3
   Web of Science ®Google Scholar
• Inzaule S, Otieno J, Kalyango J, et al. Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS One. 2014;9(4):e93106. doi:10.1371/journal.pone.0093106
   Web of Science ®Google Scholar
• Patel A, Patel K, Patel J, et al. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr. 2004;37(1):1166–1169. doi:10.1097/01.qai.0000135956.96166.f0
   Web of Science ®Google Scholar
• Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Aids. 2002;16(1):75–83. doi:10.1097/00002030-200201040-00010
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477. doi:10.1164/rccm.200206-626OC
   PubMed Web of Science ®Google Scholar
• Bezabhe WM, Bereznicki LR, Chalmers L, et al. Adverse drug reactions and clinical outcomes in patients initiated on antiretroviral therapy: a prospective cohort study from Ethiopia. Drug Saf. 2015;38(7):629–639. doi:10.1007/s40264-015-0295-7
   PubMed Web of Science ®Google Scholar
• Ottesen TD, Hsiang WR, Malpani R, et al. Underweight patients are the greatest risk body mass index group for 30-day perioperative adverse events after total shoulder arthroplasty. J Am Acad Orthop Surg. 2021;29(3):e132–e142. doi:10.5435/JAAOS-D-20-00049
   Web of Science ®Google Scholar